CN111821343A - Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof - Google Patents
Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof Download PDFInfo
- Publication number
- CN111821343A CN111821343A CN202010858277.3A CN202010858277A CN111821343A CN 111821343 A CN111821343 A CN 111821343A CN 202010858277 A CN202010858277 A CN 202010858277A CN 111821343 A CN111821343 A CN 111821343A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- extract
- chinese medicine
- liver injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 33
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 33
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims description 60
- 239000000284 extract Substances 0.000 claims abstract description 107
- 239000000843 powder Substances 0.000 claims abstract description 47
- 238000002156 mixing Methods 0.000 claims abstract description 44
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 238000007796 conventional method Methods 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 16
- 238000001914 filtration Methods 0.000 claims abstract description 16
- 238000010992 reflux Methods 0.000 claims abstract description 16
- 238000001291 vacuum drying Methods 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 12
- 239000008187 granular material Substances 0.000 claims abstract description 12
- 239000003826 tablet Substances 0.000 claims abstract description 12
- 239000004375 Dextrin Substances 0.000 claims abstract description 9
- 229920001353 Dextrin Polymers 0.000 claims abstract description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 9
- 235000019425 dextrin Nutrition 0.000 claims abstract description 9
- 239000008101 lactose Substances 0.000 claims abstract description 9
- 239000006187 pill Substances 0.000 claims abstract description 9
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- 239000005720 sucrose Substances 0.000 claims abstract description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 4
- 239000002671 adjuvant Substances 0.000 claims abstract description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 4
- 241000722941 Achillea Species 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- 238000007873 sieving Methods 0.000 claims description 28
- 239000002994 raw material Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 17
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 15
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 15
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 15
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 15
- 241000220317 Rosa Species 0.000 claims description 15
- 239000001138 artemisia absinthium Substances 0.000 claims description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 15
- 235000011477 liquorice Nutrition 0.000 claims description 15
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 240000004980 Rheum officinale Species 0.000 claims description 13
- 235000008081 Rheum officinale Nutrition 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000853 adhesive Substances 0.000 claims description 11
- 230000001070 adhesive effect Effects 0.000 claims description 11
- 241001670235 Artemisia rupestris Species 0.000 claims description 8
- 235000015784 Artemisia rupestris Nutrition 0.000 claims description 8
- 241000723343 Cichorium Species 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 4
- 240000006891 Artemisia vulgaris Species 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 13
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 13
- 238000010171 animal model Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 108090000340 Transaminases Proteins 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 102000014898 transaminase activity proteins Human genes 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 240000001851 Artemisia dracunculus Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 244000298479 Cichorium intybus Species 0.000 description 8
- 235000007542 Cichorium intybus Nutrition 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 7
- 102000016938 Catalase Human genes 0.000 description 7
- 108010053835 Catalase Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000001269 achillea millefolium l. oil Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007767 bonding agent Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The invention relates to a Chinese medicinal compound preparation for preventing and treating alcoholic liver injury and its preparation method and use, the preparation is made from herba Achillea Wilsonianae, herba Artemisiae Scopariae, herba Cichorii, flos Rosae Rugosae, radix et rhizoma Rhei, licorice, and adjuvants such as lactose, dextrin, starch, sucrose or microcrystalline cellulose by pulverizing, mixing, adding water for reflux extraction, filtering, concentrating to obtain extract with relative density of 1.0-1.2, vacuum drying to obtain dry extract, pulverizing to obtain extract powder, adding adjuvants, and making into granule, capsule, tablet or pill by conventional method. The preparation has the advantages of convenient administration and good therapeutic effect. The animal model test shows that: the Chinese medicinal compound preparation can play a remarkable role in preventing and treating alcoholic liver injury diseases. Can obviously reduce the level of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase which are indexes of clear liver injury, and has obvious prevention and protection effects on alcoholic liver injury.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine compound preparations, and particularly relates to a traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury, and a preparation method and application thereof.
Background
With the rapid growth of economy and the increasing development of society in China, the living standard of people is greatly improved, the living style and the dietary structure are changed, high calorie and high fat are greatly ingested, and alcohol is greatly consumed, so that fatty liver disease is becoming the main cause of liver disease in China. Fatty liver disease is classified into nonalcoholic liver disease (NALD) and Alcoholic Liver Disease (ALD) according to different etiologies. Nonalcoholic liver disease is largely related to unhealthy lifestyle and unhealthy diet, and cardiovascular disease is the leading cause of death of nonalcoholic fatty liver disease. Alcoholic Liver Disease (ALD) is a number of liver diseases mainly due to long-term excessive alcohol consumption, with no clinical manifestations in the early stages, ranging from simple steatosis to steatohepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). In people who drink a lot of alcohol for a long time, the alcoholic fatty liver is about 90% -100%, the alcoholic hepatitis is about 10% -35%, and the alcoholic cirrhosis is finally developed to be 8% -20%. In 1990, 373,200 people died from alcoholic cirrhosis worldwide; in 2010, 493,300 deaths were due to alcoholic cirrhosis, accounting for 47.9% of all cirrhosis deaths, 337,400 deaths were due to liver cancer, accounting for 4.2% of cancer deaths. The rate of fatality of alcoholic liver disease has increased tremendously over the past two decades, constituting a serious health hazard to humans. Worldwide, alcoholic liver disease is one of the leading causes of liver disease.
The development and development of drugs for preventing and treating alcoholic liver diseases are imminent, and many effective components in traditional Chinese medicines such as flavonoids, polysaccharides, glycosides and the like can play a role in protecting the liver. Compared with western medicines, the traditional Chinese medicine has the advantages of small toxic and side effects and low drug dependence. The Chinese medicine can be used for preventing and treating alcoholic liver injury by multiple mechanisms, such as inhibiting oxygen free radicals, improving antioxidant protease bioactivity, protecting liver function, improving ethanol metabolism, etc.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and a preparation method and application thereof, the preparation is prepared by crushing and mixing the components of artemisia rupestris, oriental wormwood, cichorium intybus, rose, rhubarb and liquorice, and the auxiliary materials are lactose, dextrin, starch, sucrose or microcrystalline fiber, adding water for reflux extraction, filtering, concentrating to obtain an extract with the relative density of 1.1, performing vacuum drying to obtain a dry extract, crushing to obtain extract powder, adding the auxiliary materials, and preparing granules, capsules, tablets or pills according to a conventional method. The preparation has the advantages of convenient administration and good therapeutic effect. The animal model test shows that: the Chinese herbal medicine compound preparation can play a significant role in protecting the liver in the prevention and treatment of alcoholic liver injury diseases. Can obviously reduce the level of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase which are indexes of clear liver injury, and has obvious prevention and protection effects on alcoholic liver injury.
The invention relates to a Chinese medicinal compound preparation for preventing and treating alcoholic liver injury, which is prepared from (by weight ratio) 1000g of radix astragali, 5-60 parts of herba Achillea Wilsonianae, 5-50 parts of herba Artemisiae Scopariae, 5-50 parts of Cichorium hirsutum, 5-50 parts of flos Rosae Rugosae, 5-30 parts of radix et rhizoma Rhei, 5-30 parts of Glycyrrhrizae radix, and 4-60 parts of lactose, dextrin, starch, sucrose or microcrystalline fiber as adjuvant by conventional method into granule, capsule, tablet or pill.
The preparation method of the traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury comprises the following steps:
a. taking 1000g as a base number, 5-60 parts of artemisia rupestris, 5-50 parts of oriental wormwood, 5-50 parts of cichorium hirsutum, 5-50 parts of rose, 5-30 parts of rheum officinale and 5-30 parts of liquorice in parts by weight, respectively crushing into coarse powder of 20-40 meshes, mixing, adding water with the volume being 15-18 times of that of the raw material medicines, carrying out reflux extraction for 2-3 times, 2-3 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and (b) adding 4-60 parts of lactose, dextrin, starch, sucrose or microcrystalline cellulose serving as auxiliary materials into the extract powder obtained in the step b according to the weight ratio of 1:2, fully and uniformly mixing, taking 65% ethanol as an adhesive, adding ethanol, wherein the ethanol is 20% -50% of the extract powder, uniformly mixing, sieving by a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound preparation of granules, capsules, tablets or pills.
The application of the traditional Chinese medicine compound preparation in preparing health-care food for preventing alcoholic liver injury.
The invention relates to a Chinese medicinal compound preparation for preventing and treating alcoholic liver injury, a preparation method and application thereof, wherein the Chinese medicinal compound preparation has the advantages that: the traditional water extraction process is adopted to extract the traditional Chinese medicine compound preparation which takes total flavonoids, phenolic acid and the like as main effective components, and animal model tests show that: the Chinese herbal medicine compound preparation can play a significant role in protecting the liver in the prevention and treatment of alcoholic liver injury.
Drawings
FIG. 1 is a graph showing the effect of the present invention on biochemical indicators of mouse serum;
FIGS. 2-4 illustrate the effect of the present invention on liver function;
FIG. 5 is a graph showing the effect of the present invention on liver lipid levels.
The specific implementation mode is as follows:
the present invention is further illustrated by the following examples.
Example 1
Granules were prepared with a base of 1000 g:
a. respectively crushing 20 parts of artemisia rupestris, 50 parts of oriental wormwood, 50 parts of cichorium hirsutum, 10 parts of rose, 10 parts of rheum officinale and 10 parts of liquorice into 20-mesh coarse powder, mixing, adding water with the volume 15 times that of the raw materials, performing reflux extraction for 2 times for 2 hours each time, combining extracting solutions, filtering, and performing reduced pressure concentration on the filtrate at the temperature of 60 ℃ until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and (b) adding 20 parts of lactose serving as an auxiliary material into the extract powder obtained in the step (b) according to a weight ratio of 1:2, fully mixing and uniformly stirring, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound granules according to a conventional method.
Example 2
Granules were prepared with a base of 1000 g:
a. respectively crushing raw material components of 60 parts by weight of alpine yarrow herb, 20 parts by weight of oriental wormwood, 20 parts by weight of cichorium intybus, 5 parts by weight of rose, 5 parts by weight of rheum officinale and 5 parts by weight of liquorice into coarse powder of 40 meshes, mixing, adding water with the volume being 16 times of that of the raw material medicines, performing reflux extraction for 3 times for 2.5 hours each time, combining extracting solutions, filtering, and performing reduced pressure concentration on the filtrate at the temperature of 60 ℃ until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 30 parts of starch serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully and uniformly mixing, adding ethanol serving as an adhesive with the concentration of 65%, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound granules according to a conventional method.
Example 3
Granules were prepared with a base of 1000 g:
a. respectively crushing raw material components of 10 parts by weight of alpine yarrow herb, 30 parts by weight of oriental wormwood, 30 parts by weight of cichorium intybus, 10 parts by weight of rose, 5 parts by weight of rheum officinale and 5 parts by weight of liquorice into coarse powder of 30 meshes, mixing, adding water with the volume being 18 times of that of the raw material medicines, carrying out reflux extraction for 2 times, 3 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at the temperature of 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 15 parts of dextrin serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully and uniformly mixing, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound granules according to a conventional method.
Example 4
Preparing capsules by taking 1000g as a base number:
a. respectively crushing 30 parts of artemisia rupestris, 20 parts of oriental wormwood, 10 parts of cichorium hirsutum, 10 parts of rose, 5 parts of rheum officinale and 5 parts of liquorice in parts by weight to obtain coarse powder of 30 meshes, mixing, adding water with the volume being 16 times that of the raw materials, performing reflux extraction for 2 times for 2 hours each time, combining extracting solutions, filtering, and performing reduced pressure concentration on the filtrate at the temperature of 60 ℃ until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 40 parts of cane sugar serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully mixing and uniformly stirring, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound capsule according to a conventional method.
Example 5
Preparing capsules by taking 1000g as a base number:
a. respectively crushing raw material components of 10 parts by weight of alpine yarrow herb, 20 parts by weight of oriental wormwood, 50 parts by weight of cichorium intybus, 20 parts by weight of rose, 10 parts by weight of rheum officinale and 10 parts by weight of liquorice into coarse powder of 40 meshes, mixing, adding water with 17 times of the volume of the raw material medicines, carrying out reflux extraction for 3 times for 2 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at the temperature of 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 30 parts of microcrystalline fiber serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully and uniformly mixing, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound capsule according to a conventional method.
Example 6
Preparing capsules by taking 1000g as a base number:
a. respectively crushing 5 parts of artemisia rupestris, 40 parts of oriental wormwood, 30 parts of cichorium hirsutum, 10 parts of rose, 10 parts of rheum officinale and 5 parts of liquorice in parts by weight into coarse powder of 20 meshes, mixing, adding water with the volume being 18 times that of the bulk drugs, carrying out reflux extraction for 2 times for 3 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at the temperature of 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 30 parts of lactose serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully mixing and uniformly stirring, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound capsule according to a conventional method.
Example 7
Tablets were prepared on a base of 1000 g:
a. respectively crushing raw material components of 60 parts by weight of alpine yarrow herb, 5 parts by weight of oriental wormwood, 30 parts by weight of cichorium intybus, 5 parts by weight of rose, 10 parts by weight of rheum officinale and 10 parts by weight of liquorice into 20-mesh coarse powder, mixing, adding water with the volume 15 times of that of the raw material medicines, performing reflux extraction for 3 times for 2 hours each time, combining extracting solutions, filtering, and performing reduced pressure concentration on the filtrate at the temperature of 60 ℃ until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 40 parts of dextrin serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully and uniformly mixing, adding ethanol by taking 65% ethanol as a bonding agent, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound tablet according to a conventional method.
Example 8
Tablets were prepared on a base of 1000 g:
a. respectively crushing 20 parts of artemisia rupestris, 20 parts of oriental wormwood, 50 parts of cichorium hirsutum, 20 parts of rose, 10 parts of rheum officinale and 10 parts of liquorice in parts by weight into coarse powder of 30 meshes, mixing, adding water with the volume being 16 times that of the bulk drugs, carrying out reflux extraction for 3 times for 3 hours each time, combining the extracting solutions, filtering, and concentrating the filtrate at the temperature of 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 30 parts of starch serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully and uniformly mixing, adding ethanol by taking 65% ethanol as a bonding agent, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound tablet according to a conventional method.
Example 9
Tablets were prepared on a base of 1000 g:
a. respectively crushing raw material components of 35 parts by weight of artemisia rupestris, 40 parts by weight of oriental wormwood, 10 parts by weight of cichorium hirsutum, 20 parts by weight of rose, 10 parts by weight of rheum officinale and 10 parts by weight of liquorice into coarse powder of 40 meshes, mixing, adding water with the volume being 18 times of that of the raw material medicines, carrying out reflux extraction for 3 times for 2 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at the temperature of 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 35 parts of microcrystalline cellulose serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully and uniformly mixing, adding ethanol by taking 65% ethanol as a bonding agent, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound tablet according to a conventional method.
Example 10
Pellets were prepared on a base of 1000 g:
a. respectively crushing 5 parts of shortstalk monkshood root, 50 parts of oriental wormwood, 30 parts of cichorium intybus, 10 parts of rose, 5 parts of rhubarb and 5 parts of liquorice into coarse powder of 40 meshes, mixing, adding water with the volume 15 times of that of the raw material medicines, carrying out reflux extraction for 2 times, 3 hours each time, combining extracting solutions, filtering, and carrying out reduced pressure concentration on the filtrate at the temperature of 60 ℃ until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 40 parts of lactose serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully mixing and uniformly stirring, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound pill according to a conventional method.
Example 11
Pellets were prepared on a base of 1000 g:
a. respectively crushing raw material components of 40 parts by weight of alpine yarrow herb, 40 parts by weight of oriental wormwood, 10 parts by weight of cichorium intybus, 5 parts by weight of rose, 20 parts by weight of rheum officinale and 20 parts by weight of liquorice into coarse powder of 20 meshes, mixing, adding water with 17 times of the volume of the raw material medicines, carrying out reflux extraction for 3 times for 2 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at the temperature of 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 30 parts of dextrin serving as an auxiliary material into the extract powder obtained in the step b according to the weight ratio of 1:2, fully and uniformly mixing, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound pill according to a conventional method.
Example 12
Pellets were prepared on a base of 1000 g:
a. respectively crushing raw material components of 60 parts by weight of alpine yarrow herb, 5 parts by weight of oriental wormwood, 5 parts by weight of cichorium intybus, 10 parts by weight of rose, 50 parts by weight of rheum officinale and 50 parts by weight of liquorice into coarse powder of 30 meshes, mixing, adding water with the volume being 18 times of that of the raw material medicines, carrying out reflux extraction for 3 times, 3 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at the temperature of 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and c, adding 30 parts of cane sugar serving as an auxiliary material into the extract powder obtained in the step b according to a weight ratio of 1:2, fully and uniformly mixing, adding ethanol by taking 65% ethanol as an adhesive, uniformly mixing, sieving by using a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound pill according to a conventional method.
Example 13
The test of the compound Chinese medicine preparation of any one of the embodiments 1 to 12 on the alcohol-induced liver injury model of mice:
experimental animals: ICR mice, weighing 13-15g, purchased from the animal center of Xinjiang medical university;
the kit comprises: DPPH, ABTS, Tris-base, DMSO and protease inhibitor (PMSF) were purchased from Sigma, USA; glutamic-oxaloacetic transaminase (AST), glutamic-pyruvic transaminase (ALT), Catalase (CAT) kit, glutathione peroxidase (GSH-PX) kit, total superoxide dismutase (T-SOD) kit, Malondialdehyde (MDA) kit, Lactate Dehydrogenase (LDH) kit, Total Cholesterol (TC) and Triglyceride (TG) which are purchased from Nanjing to build a bioengineering institute; the Nitric Oxide (NO) detection kit is purchased from Biyuntian biotechnology limited; interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and transforming growth factor beta (TGF-beta) were purchased from Union Biotechnology, Inc.; primary anti-COX-2, iNOS, P-NF-. kappa.B, P-ERK1/2, ERK1/2, P-P38MAPK, and β -actin were purchased from Cell Signal Technology, USA; primary anti-Nrf 2 and HO-1 antibodies were purchased from Abcam, uk; CYP2E1 antibody is purchased from Millipore, USA; the secondary antibody rabbit anti-horseradish peroxidase HRP is purchased from Shanghai Boseudo; 5 × Loading buffer and skimmed milk powder were purchased from Shanghai Boshide; tween 20 was purchased from tianjin century chemical; 30% ACR-BASE from Beijing Bootuotu; ECL luminophore kit was purchased from Thermo Scientific, USA;
experimental samples: chinese medicinal compound preparation;
the experimental scheme is as follows: the mice are fed adaptively for 7 days before the experiment, 48 ICR mice of 13-15g are taken and randomly divided into 6 groups, and each group comprises 8 mice, namely a control group, an alcoholic liver injury model group, a positive control group, a low dose group, a medium dose group and a high dose group; in a control group and a model group, the mice are given with the same amount of diluent, in a positive control group, the mice are orally taken with silybin (79.1mg/Kg), three groups of mice are respectively orally taken with a traditional Chinese medicine compound preparation with the low dose of 1.5g/Kg, the medium dose of 3g/Kg and the high dose of 6g/Kg for 4 weeks, 1 hour after administration, the control group is injected with the same amount of normal saline in the abdominal cavity, and the rest groups are injected with 5ml/Kg of 56 percent ethanol in the abdominal cavity to induce liver injury;
(1) the traditional Chinese medicine compound preparation has the following effects on biochemical indexes of mouse serum:
compared with a control group (Cont), the activities of serum AST, ALT and ALP of an alcoholic liver injury model (EtOH) group are obviously improved (p is less than 0.05), and the EtOH group is prompted to have liver dysfunction; positive control group (SILY group), medium dose group (XM group), high dose group (XH group) ALP level was significantly decreased (p < 0.05); ALT and AST activity decreased in SILY group (p <0.05) and XH group (p < 0.05); the Chinese medicinal compound preparation is shown in figure 1, which shows that the Chinese medicinal compound preparation has certain improvement effect on the alcoholic liver injury of mice;
(2) the traditional Chinese medicine compound preparation has the following antioxidation effect in the liver:
taking a plurality of antioxidases as parameters for evaluating the oxidative stress level of the liver of the mouse; the activities of glutathione peroxidase (GSH-PX), total superoxide dismutase (T-SOD) and Catalase (CAT) are obviously reduced in alcohol group liver (p is less than 0.05); the oxidation product Malondialdehyde (MDA) of the alcohol group is obviously higher than that of the control group (p < 0.05); the changes are corrected by the traditional Chinese medicine compound preparation, three dosage groups of the traditional Chinese medicine compound preparation can obviously improve the T-SOD and CAT activities (p is less than 0.05) of mice with alcoholic liver injury, compared with an alcohol group, the GSH-PX activities of XL and XH groups are obviously improved (p is less than 0.05), each dosage group of the traditional Chinese medicine compound preparation can reduce the MDA level (p is less than 0.05), and the data show that the traditional Chinese medicine compound extract has good antioxidant capacity in vivo as shown in Table 1;
TABLE 1
(3) The influence of the traditional Chinese medicine compound preparation on the liver function is as follows:
the influence of the traditional Chinese medicine compound preparation on liver functions is researched, wherein the traditional Chinese medicine compound preparation comprises glutamic-pyruvic transaminase (AST), alanine Aminotransferase (ALT), hydroxyproline, Nitric Oxide (NO) and Lactate Dehydrogenase (LDH), the AST and ALT activities of an alcoholic liver injury model (EtOH) group are obviously improved (p is less than 0.05), the AST (p is less than 0.05) can be obviously reduced in an XL, XM and XH group, the AST (p is less than 0.05) can be also obviously reduced in an SILY group, and the ALT reduction (p is less than 0.05) of the XH group and the SILY group is shown in figure 2;
compared with a control group, the hydroxyproline level of a model group is obviously increased (p <0.05), as shown in figure 3, the hydroxyproline increase can be reduced by supplementing the traditional Chinese medicine compound preparation and silymarin, particularly, as shown in figure 4 in an XH group (p <0.05), compared with a Cont group, the NO and LDH levels of an EtOH group are increased, the NO level of an XM group and the NO level of an XH group are reduced (p <0.05) by the traditional Chinese medicine compound preparation, and the LDH content of the XH group is also reduced (p < 0.05);
(4) the influence of the traditional Chinese medicine compound preparation on the liver lipid level:
the blood lipid level of the liver of a mouse is measured by taking Total Cholesterol (TC) and Triacylglycerol (TG) as common biochemical indicators of blood lipid, the blood lipid level is shown in figure 5, the contents of TC and TG in an EtOH group are increased compared with a Cont group, but the difference is not obvious, in mice treated by a traditional Chinese medicine compound preparation, the TC contents in an XM group and an XH group are obviously reduced (p is less than 0.05), the triglyceride content in the XM group is reduced (p is less than 0.05), and other administration groups have the tendency of reducing action, and the result shows that: the Chinese medicinal compound preparation has the effect of improving liver lipid level;
(5) the influence of the traditional Chinese medicine compound preparation on the level of the liver cell factors is as follows:
tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor beta (TGF-beta) were significantly elevated (p <0.05) in the alcoholic liver injury model (EtOH) group. However, TNF- α TGF- β significantly (p <0.05) reduced XM and XH groups of the liver; the liver interleukin-6 (IL-6) content of the EtOH group is higher than that of the Cont group, but the difference has no statistical significance; silymarin and Chinese medicinal compound preparation can inhibit increase of IL-6 in mice with alcoholic liver injury;
and (4) conclusion: the traditional Chinese medicine compound preparation has obvious effect of reducing the content of AST, ALT and ALP in serum of mice with alcoholic liver injury, and can also reduce the content of AST, ALT, hydroxyproline, Nitric Oxide (NO) and Lactate Dehydrogenase (LDH) in liver of the mice; the traditional Chinese medicine compound preparation can improve the liver function of an alcoholic liver injury mouse, simultaneously, the content activities of three enzymes of CAT, GSH-PX and T-SOD are obviously reduced in an alcoholic liver injury model mouse, the activities of CAT, GSH-PX and T-SOD are obviously improved after the traditional Chinese medicine compound preparation is treated, Malonaldehyde (MDA) is a lipid peroxidation mark, the content of malonaldehyde is obviously reduced after the traditional Chinese medicine compound preparation is administered, and the result shows that: the Chinese medicinal compound preparation can relieve oxidative stress induced liver injury by antioxidant activity.
Claims (3)
1. A traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury is characterized in that: the preparation is prepared from 1000g of herba Achillea Wilsonianae as basic material, 5-60 parts of herba Artemisiae Scopariae, 5-50 parts of herba Cichorii, 5-50 parts of flos Rosae Rugosae, 5-30 parts of radix et rhizoma Rhei, 5-30 parts of Glycyrrhrizae radix, and 4-60 parts of lactose, dextrin, starch, sucrose or microcrystalline fiber as adjuvant by conventional method, and can be made into granule, capsule, tablet or pill.
2. The preparation method of the compound traditional Chinese medicine preparation for preventing and treating alcoholic liver injury according to claim 1 is characterized by comprising the following steps:
a. taking 1000g as a base number, 5-60 parts of artemisia rupestris, 5-50 parts of oriental wormwood, 5-50 parts of cichorium hirsutum, 5-50 parts of rose, 5-30 parts of rheum officinale and 5-30 parts of liquorice in parts by weight, respectively crushing into coarse powder of 20-40 meshes, mixing, adding water with the volume being 15-18 times of that of the raw material medicines, carrying out reflux extraction for 2-3 times, 2-3 hours each time, combining extracting solutions, filtering, and concentrating the filtrate at 60 ℃ under reduced pressure until the relative density is 1.1 to obtain an extract;
b. vacuum drying the extract obtained in the step a to obtain dry extract, and then crushing the dry extract and sieving the crushed dry extract with a 80-mesh sieve to obtain extract powder;
c. and (b) adding 4-60 parts of lactose, dextrin, starch, sucrose or microcrystalline cellulose serving as auxiliary materials into the extract powder obtained in the step b according to the weight ratio of 1:2, fully and uniformly mixing, taking 65% ethanol as an adhesive, adding ethanol, wherein the ethanol is 20% -50% of the extract powder, uniformly mixing, sieving by a 10-mesh sieve, drying at the temperature of 60 ℃, and preparing the traditional Chinese medicine compound preparation of granules, capsules, tablets or pills.
3. The use of the compound traditional Chinese medicine preparation according to claim 1 in the preparation of health food for preventing alcoholic liver injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010858277.3A CN111821343A (en) | 2020-08-24 | 2020-08-24 | Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010858277.3A CN111821343A (en) | 2020-08-24 | 2020-08-24 | Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111821343A true CN111821343A (en) | 2020-10-27 |
Family
ID=72917832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010858277.3A Pending CN111821343A (en) | 2020-08-24 | 2020-08-24 | Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111821343A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127273A (en) * | 2013-03-12 | 2013-06-05 | 中国科学院新疆理化技术研究所 | Compound medicament for treating chronic liver disease and preparation method thereof |
| CN103127305A (en) * | 2013-03-13 | 2013-06-05 | 南京中医药大学 | Traditional Chinese medicine preparation with auxiliary protection function on alcoholic liver injury and preparation method thereof |
| CN105560475A (en) * | 2015-12-21 | 2016-05-11 | 新疆环拓生物科技有限公司 | Traditional Chinese medicine composition for preventing chemical liver injury and preparation method thereof |
| CN106511838A (en) * | 2016-12-30 | 2017-03-22 | 河南中医药大学 | Traditional Chinese medicinal granules for treating alcoholic liver injury |
-
2020
- 2020-08-24 CN CN202010858277.3A patent/CN111821343A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127273A (en) * | 2013-03-12 | 2013-06-05 | 中国科学院新疆理化技术研究所 | Compound medicament for treating chronic liver disease and preparation method thereof |
| CN103127305A (en) * | 2013-03-13 | 2013-06-05 | 南京中医药大学 | Traditional Chinese medicine preparation with auxiliary protection function on alcoholic liver injury and preparation method thereof |
| CN105560475A (en) * | 2015-12-21 | 2016-05-11 | 新疆环拓生物科技有限公司 | Traditional Chinese medicine composition for preventing chemical liver injury and preparation method thereof |
| CN106511838A (en) * | 2016-12-30 | 2017-03-22 | 河南中医药大学 | Traditional Chinese medicinal granules for treating alcoholic liver injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN103300188A (en) | Tartary buckwheat granule tea capable of reducing blood glucose, and preparation method thereof | |
| CN115364170B (en) | Sugar metabolism regulator and preparation method and application thereof | |
| CN110893197B (en) | Panax notoginseng extract for treating gout and preparation method thereof | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN101947296A (en) | Chinese medicine composition for treating diabetes | |
| CN101618096A (en) | Madder extract and preparation method and application thereof | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN110051817A (en) | A kind of Chinese traditional medicine composition and its application reducing uric acid | |
| CN111821343A (en) | Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof | |
| CN106265717B (en) | Application of the dicliptera chinensis polysaccharide in preparing prevention diabetes medicament or health products | |
| CN102579587B (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof | |
| CN102631425B (en) | Mongolian medicine for treating dyslipidemia | |
| CN102178792B (en) | Shiqi exogenous Chinese medicinal buccal tablets | |
| CN114747766A (en) | Health-care food composition capable of reducing uric acid and preparation method and application thereof | |
| CN111700927B (en) | Medicinal and edible composition with blood sugar reducing effect and preparation method and application thereof | |
| KR20150046916A (en) | Compositions for treating or preventing liver fibrosis or cirrhosis | |
| KR100685472B1 (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome | |
| CN102552828B (en) | Liver protecting medicine and preparation method thereof | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CN105535070B (en) | The pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201027 |
|
| WD01 | Invention patent application deemed withdrawn after publication |